AstraZeneca Leverages RWD and RWE for New Therapeutic Development

Real-world data (RWD) and real-world evidence (RWE) are increasingly used in clinical development and market access. AstraZeneca is using these resources to help develop its next set of therapeutics, many of which target cardiovascular pathologies. To do so, the company’s R&D team pulls RWD from available sources of electronic health records (EHR).

According to ZS, “To ensure analytical focus on the most interesting and meaningful questions, as well as consistent support and collaborative ideation, we followed a high-touch iterative working model that helped us achieve our goals for the program.”

To read more, click here.

(Source: ZS, September 28^th, 2022)